Abstract:Precision medicine relies on the idea that, for a particular targeted agent, only a subpopulation of patients is sensitive to it and thus may benefit from it therapeutically. In practice, it is often assumed based on preclinical data that a treatment-sensitive subpopulation is known, and moreover that the agent is substantively efficacious in that subpopulation. Due to important differences between preclinical settings and human biology, however, data from patients treated with a new targeted agent often show that one or both of these assumptions are false. This paper provides a Bayesian randomized group sequential enrichment design that compares an experimental treatment to a control based on survival time and uses early response as an ancillary outcome to assist with adaptive variable selection and enrichment. Initially, the design enrolls patients under broad eligibility criteria. At each interim decision, submodels for regression of response and survival time on a baseline covariate vector and treatment are fit; variable selection is used to identify a covariate subvector that characterizes treatment-sensitive patients and determines a personalized benefit index, and comparative superiority and futility decisions are made. Enrollment of each cohort is restricted to the most recent adaptively identified treatment-sensitive patients. Group sequential decision cutoffs are calibrated to control overall type I error and account for the adaptive enrollment restriction. The design provides a basis for precision medicine by identifying a treatment-sensitive subpopulation, if it exists, and determining whether the experimental treatment is superior to the control in that subpopulation. A simulation study shows that the proposed design reliably identifies a sensitive subpopulation, yields much higher generalized power compared to several existing enrichment designs and a conventional all-comers group sequential design, and is robust.

Bayesian Two-Stage Sequential Enrichment Design for Biomarker-Guided Phase II Trials for Anticancer Therapies.

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

A signature enrichment design with Bayesian adaptive randomization

Optimal Sequential Enrichment Designs for Phase II Clinical Trials.

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Two-Stage Adaptive Enrichment Designs with Survival Outcomes and Adjustment for Misclassification in Predictive Biomarkers

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

A Bayesian Phase I/II Trial Design for Immunotherapy

A Bayesian Piecewise Exponential Phase II Design for Monitoring a Time‐to‐event Endpoint

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Shotgun: A Bayesian Seamless Phase I-II Design to Accelerate the Development of Targeted Therapies and Immunotherapy.

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Biomarker-Guided Adaptive Enrichment Design with Threshold Detection for Clinical Trials with Time-to-Event Outcome

Bayesian Optimal Phase II Design for Randomized Clinical Trials

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.

An adaptive seamless 2-in-1 design with biomarker-driven subgroup enrichment